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M icrorNAs (mirNAs) are short, noncoding rNA molecules composed of a single-stranded sequence 
of 20 to 24 nucleotides. They predominantly act as nega-
tive regulators of gene expression.1,2 Functionally, they regu-
late target genes at the posttranscriptional level via means 
of preventing the synthesis of the active protein. This can 
be achieved by binding of mirNAs to protein-coding tran-
scripts, thereby preventing either translation of the mrNA 
to a functional protein or leading to mrNA degradation. 
Being involved in the regulation of essentially every aspect 
of cellular function, it is hardly surprising that mirNAs 
are thought of as critical regulators during various disease 
processes, such as sepsis, ischemia–reperfusion, or cancer.3–7 
mirNAs were first discovered in 1993 in studies reporting 
mirNA–mrNA interaction in Caenorhabditis elegans.8 sim-
ilar to double-stranded rNA molecules manipulating gene 
expression by rNA interference as described by Nobel Prize 
winners Fire and Mello in nematodes,9 mirNAs were ini-
tially thought to be only relevant in nonmammalian species. 
However, it was subsequently identified that mirNAs are 
expressed in mammalian systems and play important func-
tional roles.10,11 From that time onward, mirNA research 
focused on screening mirNA expressions in various human 
tissues and disease processes. Many of these studies revealed 
that mirNAs are expressed in tissue-specific patterns and 
play fundamental roles in tissue identity and in character-
istic features of cell types and functions.12,13 initial analysis 
of mirNA expressions in diverse human pathologic states 
clearly revealed correlations between mirNA expression pat-
terns and certain human diseases including inflammatory 
conditions and sepsis, ischemia–reperfusion, or cancer.3,7,14 
subsequent studies focusing on mirNAs functional activi-
ties leveraged the importance of mirNAs as critical gene 
regulators and indicated the potential clinical relevance of 
mirNAs. Not only could mirNA expression patterns pro-
vide a new diagnostic tool, but also would aberrant mirNA 
functions present promising new therapeutic options by 
targeting mirNAs. Another conceivable application for 
mirNAs in a clinical setting is related to the emerging field 
of personalized medicine. indeed, many studies point out 
the prognostic importance of mirNA expression. important 
distinction between certain states of diseases (e.g., subtypes 
of tumor entities) could lead to improved identification of 
the best suitable therapeutic treatment for a specific patient. 
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For example, in the field of perioperative medicine, mirNA 
expression variations may serve as preoperative biomarkers to 
stratify the individual patient risks for specific organ injuries. 
The clinical availability of mirNAs could improve detecting 
preexisting risks for postoperative complications and thereby 
help preventing fulminant organ failure or severe inflamma-
tory response following intervention. some in vitro studies 
even indicate that mirNAs could play a functional role in 
neuroprotection from anesthetic toxicity.15,16 The present 
review aims to provide the reader with an understanding of 
the function and disease implications of mirNAs. For this 
purpose, we attempted to include a discussion of exciting 
research studies from the field of mirNAs that could have 
an important impact on the perioperative medicine. More-
over, we are highlighting various scenarios of how mirNAs 
could enter daily anesthesia care of various patients and out-
line their potential impact on emergency, critical care, and 
perioperative medicine (fig. 1).
Biological Functions
Maturation
To understand mirNA functions, it is important to be aware 
of the mechanism that regulates mirNA biogenesis. mirNA 
genes are located throughout the genome and can be found 
intergenic (in non–protein-coding regions) or in genomic 
regions that are within protein-coding genes and are there-
fore cotranscribed with the host gene.17 mirNA biogenesis 
starts similar to the majority of protein-coding genes in the 
nucleus. in contrast, later maturation steps are different 
from other small rNAs (fig. 2). in the nucleus, rNA poly-
merase ii (Pol ii) generates long primary transcripts called 
pri-mirNAs,18 which will then be further processed by 
two mirNA exclusive rNase iii enzymes: Drosha and 
Dicer. The first one associates with a nuclear protein called 
DiGeorge syndrome critical region 8 and produces a 
hairpin- structured shorter precursor mirNA named pre-
mirNA, which subsequently is exported into the cyto-
plasm. After the nuclear export, the critical second nuclease 
Dicer further shortens the pre-mirNA, resulting in an 
unstable double-stranded short mirNA. one strand of this 
duplex structure becomes the functionally active mirNA, 
which gets incorporated into a nuclease complex called the 
rNA-induced silencing complex (risc). The active single-
stranded mirNA within the risc subsequently interacts 
with its mrNA target and induces nuclease activity, thereby 
regulating protein expression.2,19–22 According to an mirNA 
database entry (mirBase 21, a database of all published 
mirNA sequences, released in July 2014), a total of 1,881 
human mirNA loci have been presently described.
Regulation of miRNA Expression
MicrorNA maturation is a tightly regulated process, includ-
ing temporal and spatial coordination. Any dysregulation of 
mirNA biogenesis can alter the mirNA expression levels, 
which in turn can cause altered gene expression, thereby 
potentially contributing to disease. For example, this pro-
cess has been implicated in the initiation of various cancers. 
Among many proteins involved in the proper maturation 
process, the most critical checkpoints are rNase iii pro-
teins and associated nuclear proteins DiGeorge syndrome 
critical region 8, Drosha, and Dicer. Their proper function 
is essential for mammalian life, as it was shown in genetic 
models that mice with global genetic deletion of any of these 
“mirNA maturation enzymes” are not viable.23,24
in addition to regulatory elements of the mirNA matu-
ration process, pathways that control tissue-specific mirNAs 
Fig. 1. MicroRNA (miRNA) functions in perioperative medi-
cine. miRNAs represent targets for diagnostic or therapeu-
tic approaches in various perioperative fields. A subset of 
miRNAs of which inhibition or overexpression has shown 
therapeutic promise are currently being pursued as clinical 
candidates for disease treatment or prevention. For example, 
in the setting of “cardiovascular disease,” targeting miR-155 
in patients with arteriosclerosis could reduce one of the main 
risk factors for myocardial infarction or stroke.58 Detecting 
levels of miR-208a in the peripheral blood of patients with 
suspect of heart attacks could improve the early diagnosis 
and consequently accelerate therapeutic onset as its in-
crease was shown to occur in the very first hours postinfarc-
tion.104 As a target for “inflammation,” detection of miR-146a 
could help modulating immune-mediated pathology because 
miR-146a was shown to regulate the suppressive activity 
of regulatory T cells.85 In the setting of “sepsis or infection,” 
patients suffering from chronic hepatitis C virus infection 
can be successfully treated with SPC 3649, a drug that tar-
gets miR-122 and thereby reduces hepatitis C virus replica-
tion.103 Identified in studies of “aging” individuals, pharma-
cologic approaches inhibiting miR-34a (e.g., anti-miR-34a) 
could improve cardiac function.72 During anesthesia, specific 
miRNAs could represent promising candidates to protect 
from anesthesia-induced neurotoxicity. For example, ex-
perimental overexpression of miR-21 was found to attenuate 
the cell death of human embryonic stem cell–derived neu-
rons induced by propofol.15 Other miRNAs are implicated in 
mediating “perioperative organ protection,” for example, 
miR-21 was shown to have a functional role during myocar-
dial ischemia–reperfusion injury.152
Copyright © 2015, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Anesthesiology 2016; 124:489-506 491 Neudecker et al.
EDUCATION
expression have been described as well. For instance, some 
mirNAs are differentially processed after the pre-mirNA 
maturation. Depending on the tissue, ubiquitously expressed 
pre-mirNAs are selectively exported into the cytoplasm for 
further maturation.25
An additional level of mirNA expression control relates 
to mirNA decay. rapid changes in mirNA expression 
allow for mirNAs to frequently react faster than other sys-
tems, thereby highlighting the high turnover rate of mature 
mirNAs. Even though the risc-incorporated mirNA is 
considered to be relatively stable (e.g., half-lives of several 
hours to days26,27), individual mirNAs have shown differ-
ences in mirNA stability.27 These differences indicate that 
mirNA turnover is also involved in mirNA expression reg-
ulation. in particular in the neuronal system, active mirNA 
degradation was found to play a critical role,28 and various 
brain-specific mirNAs revealed to have short half-lives com-
pared with mirNAs in other systems.
Transcriptional regulation of mirNA expression can be 
controlled via classical transcription factors via binding of 
such transcription factors to the promoter region of genes 
encoding mirNAs. For example, during conditions of lim-
ited oxygen availability (hypoxia), the transcription factor 
hypoxia-inducible factor (HiF) is stabilized and was shown 
to regulate a panel of mirNAs. By direct binding to mirNA 
promoters, HiF can cause induction or repression of a gene. 
in addition, some of these mirNAs can target HiF (reviewed 
in the study by shen et al.29). These interactions between 
mirNAs and HiF are feedback loops that are relevant to cel-
lular processes such as proliferation, cell cycle progression, or 
angiogenesis, processes playing a role in tumorigenesis, but 
also in ischemia–reperfusion.
Mechanisms of Target Regulation
MicrorNAs predominantly act as negative regulators of gene 
expression.19 in the majority of cases, mirNAs identify and 
bind their target gene in a specific mrNA region. Protein-
coding mrNAs are organized in three main regions. Those 
regions are the five prime untranslated region (5′UTr), the 
three prime untranslated region (3′UTr), and the coding 
region or also called open reading frame, which is flanked by 
the two untranslated regions. The coding region ultimately 
contains the genetic information of the gene, which on a 
DNA level is composed of multiple regions, called introns 
and exons (fig. 3A). The final protein composition is defined 
by the sequence of bases within the exons, thereby making 
up the translated region of the mrNA. mirNAs preferen-
tially bind their target mrNA in the 3′UTr of the mrNA. 
This is the mrNA region located downstream of the coding 
region. The 3′UTr is usually not translated into protein but 
Fig. 2. MicroRNA (miRNA) biogenesis. miRNA biogenesis starts in the nucleus where RNA polymerase II (Pol II) generates large 
transcripts called primary miRNAs (pri-miRNA). Next, associated with DiGeorge Syndrome Critical Region 8 protein (DGCR 8), 
RNase nuclease Drosha synthesizes shorter hairpin-structured precursor miRNAs (pre-miRNA). The pre-miRNA is exported from 
the nucleus into the cytosol where RNase nuclease Dicer further shortens the hairpin-structured miRNA, resulting in double-
stranded short duplex miRNAs. The mature strand gets incorporated into RNA-induced silencing complex (RISC) and guides 
this multiprotein complex to the target mRNA for gene repression. Binding of the miRNA to complementary sequences in the 3 
prime untranslated region (3′UTR) of the mRNA of a target gene typically results in translational repression or mRNA degradation, 
thereby causing functional repression of the target gene.
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serves as regulatory region that can affect posttranscriptional 
processes and subsequently gene expression. mirNA bind-
ing initiates the risc-mediated gene regulation, resulting 
in mrNA degradation or translational repression (fig. 3B). 
in rare cases, mirNAs can also bind outside the 3′UTr, for 
example, in the 5′UTr or even in the coding region.30–33 
mirNA–mrNA base pairing in the 3′UTr prevents any 
further steps that could lead to the synthesis of a full protein 
encoded by the targeted mrNA. This regulatory function 
does not require perfect base pairing between mirNA and 
targeted mrNA. Therefore, a single mirNA can target many 
different mrNAs, leading to a wide scope of mrNA altera-
tions (fig. 3c). However, one target mrNA can be repressed 
by multiple different mirNAs34 (fig. 3c). initially, it was 
assumed that mirNAs predominantly act as translational 
repressors.35,36 Today, mirNA-mediated gene silencing is 
thought to affect both the levels of mrNA and the level of 
synthesized protein.37–40 This complex network of mirNA–
mrNA interactions explains the fact that the expression of 
more than 60% of all human genes are thought to be fine-
tuned by mirNAs.41
Secreted miRNAs
only recently discovered, mirNAs can also participate in 
intercellular communication, such as cross-talk between 
different cell types. As such, studies demonstrated that 
mirNAs can represent genetic information that is passed on 
from one cell type to another and thereby participating in 
the exchange of genetic information. cell–cell communica-
tion based on mirNA exchange can take place within a tis-
sue or among different cell types. The finding of extracellular 
mirNAs as a means of intercellular communication is 
intriguing from a clinical perspective. These findings high-
light that mirNAs are not only not limited to intracellular 
functions. instead, mirNAs can exist in the extracellular 
compartment and have the capability to participate in inter-
cellular communication.42,43 mirNAs were found in various 
human body fluids, including blood, urine, cerebrospinal 
fluid, bronchoalveolar lavage, or breast milk. Extracellular 
mirNAs are easily detectable in human body fluids and pro-
vide an additional noninvasive instrument to analyze patients’ 
“health” state. Additional studies identified extracellular ves-
icles and lipids serving as carrier vehicles in mirNA-based 
cell–cell interactions.42,44,45 Membrane-enclosed or lipid-
bound secreted mirNAs are surprisingly stable46 and can be 
taken up by recipient cells.47,48 The exact mechanisms under-
lying this genetic exchange including mirNA selection and 
packaging and the process of transport and uptake are still 
not fully understood. However, it is becoming increasingly 
apparent that mirNAs can transfer signals between immune 
cells, thereby orchestrating acute immune response.47,49 
other studies implicate mirNA transfer in chronic diseases 
such as atherosclerosis50,51 or in promoting tumor growth 
and metastasis.43,52 For example, mir-150 was found to 
be contained in extracellular microvesicles in the plasma of 
patients with atherosclerosis. subsequent studies indicate 
that mir-150 mediates a cross-talk between blood cells and 
the vasculature. In vitro and in vivo experiments revealed 
that blood cell–secreted microvesicles containing mir-150 
were delivered into blood vessel cells, where increased levels 
of mir-150 regulated cell migration (by targeting its target 
c-Myb).44 c-Myb is a family member of the MYB transcrip-
tion factors, a family of proteins including the conserved 
MYB DNA-binding domain. The MYB protooncogene was 
shown to play an essential role in tumorigenesis by regu-
lating migration and tumor invasiveness, for example, in 
breast and colon cancer.53 The existence of functional active 
extracellular mirNAs indicates a very auspicious approach 
Fig. 3. MicroRNA (miRNA) functions. (A) Structure of mRNAs, 
transcribed from DNA. mRNAs are composed of three main 
regions: the 5 prime and 3 prime untranslated regions (5′UTR 
and 3′UTR) representing regions that are not translated into 
proteins. The untranslated regions flank the coding region or 
open reading frame (ORF). The ORF is composed of exons 
and introns, with only the exons being eventually translated 
into proteins. (B) Mature miRNAs are loaded into the RNA-
induced silencing complex (RISC) and guide the RISC to the 
target mRNA. miRNA binding to its mRNA target sequence 
typically occurs within the 3′UTR of the mRNA. This process 
results in gene regulation, either by translational repression or 
mRNA degradation. (C) One single miRNA can bind to many 
different mRNA targets and therefore it regulatory can have 
a wide scope. However, one target mRNA can be repressed 
by different miRNAs, ensuring a profound miRNA-mediated 
regulatory effect.
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for patient care. one could potentially take the advantage 
of modulating these endogenous regulators for diagnostics 
purposes or in order to optimize therapeutic strategies for 
instance during inflammatory disease conditions or during 
infections with pathogens.
miRNA Functions in Perioperative Medicine
Cardiovascular Disease
shortly after discovering mirNAs in mammalians, mirNA 
profiling studies revealed correlations between mirNA 
expression patterns and human diseases.3,6 Numerous stud-
ies in various human vascular and cardiac diseases affirmed 
that mirNAs play a critical role in cardiovascular disor-
ders. Functional studies attribute significant roles for those 
mirNA with aberrant expressions in the development and 
maintenance of cardiovascular disorders, including myo-
cardial infarction, heart failure, and fibrosis.54–57 Here, in 
particular, we want to focus on mirNAs involved in the 
pathogenesis of arteriosclerosis (mir-155) and mirNAs 
that contribute to myocardial dysfunction and heart failure 
(mir-208a and mir-34a).
studies focusing on arteriosclerosis analyzed mirNA 
expression in human carotid plaques, obtained during 
carotid endarterectomy. These studies revealed increased 
expression levels of mir-155 and mir-147b.58 subsequent 
studies in murine macrophages in an in vivo mouse model 
of arteriosclerosis confirmed that mir-155 promotes the 
proinflammatory activity of macrophages and that the lack 
of mir-155 in vivo leads to markedly reduced arteriosclero-
sis. Mir-155 was shown to directly repress the expression 
of B-cell lymphoma 6 (BcL6) protein, a transcription fac-
tor involved in the control of inflammation. BcL6 inhibits 
proinflammatory signaling, leading to attenuation of athero-
sclerosis.59 This antiinflammatory effect of BcL6 is partially 
mediated by inhibition of nuclear factor κ-light-chain-
enhancer of activated B cells signaling via different mecha-
nisms. Together with the high levels of mir-155 found in 
human arteriosclerotic plaques,58 these findings indicate that 
inhibition of mir-155 could be a novel therapeutic approach 
to the treatment of arteriosclerosis.
Myocardial infarction and heart failure are among the 
most frequent perioperative complication during noncar-
diac surgeries.60 A study in hypertrophic or failing hearts 
from humans revealed 12 mirNAs that are modulated 
compared with healthy controls.61 subsequent studies iden-
tified mir-208a as important modulator of the cardiac 
stress response.62 interestingly, this mirNA is cardiac spe-
cific. The cardiomyocyte-specific expression pattern indi-
cates a significant role of this mirNA in the regulation of 
myocardial function.60 Mice carrying a genetic deletion 
of mir-208a showed reduced hypertrophy and fibrosis in 
response to cardiac stress.62 Moreover, mir-208a knockout 
mice were unable to up-regulate pathologic cardiac mark-
ers suggesting that inhibition of mir-208a is beneficial in 
cardiac stress and, in a broader sense, in the context of heart 
disease. Pharmacologic inhibition of mir-208a in murine 
studies confirmed this potential advantage during cardiac 
stress and also ascribed promising pharmacologic features to 
the selected inhibition of this mir-208a using a so-called 
“locked nucleic acid” (LNA) specifically targeting this 
mirNA in vivo.63 Myocardial contractility largely depends 
on the contractile protein Myosin Heavy chain (MHc). 
Two MHc isoforms represent this major contractile protein 
of the cardiac muscle, α-MHc and β-MHc. Up-regulation 
of mir-208a lead to increased β-MHc expression and 
was associated with arrhythmia, fibrosis, and hypertrophic 
growth in mice.64 in addition, mir-208a was revealed to 
be a strong predictor of cardiac death and heart failure.65 
However, it was shown that down-regulation or deletion of 
mir-208a was associated with decreased β-MHc expres-
sion in the adult heart64,66 and attenuated pathologic cardiac 
remodeling.63,64 Additional studies provided more insights 
into the positive effects of reduced mir-208a expression by 
revealing an unexpected resistance to obesity after mir-208a 
inhibition.67 The authors found that mir-208a inhibition 
in mice lead to a resistance to high-fat diet–induced obesity. 
inhibition of mir-208a caused increased levels of its target 
mediator complex subunit 13 (Med13), which is involved 
in the regulation of energy expenditure and regulation of 
numerous genes involved in energy balance in the heart. 
MED13 represents a transcriptional coactivator complex 
that is thought to be required for the expression of almost all 
genes. it serves as the molecular bridge between the general 
transcriptional machinery with specific transcription factors 
and the kinase submodules.68 According to these findings, 
mir-208a qualifies as a potent target for therapeutic modu-
lation of cardiac function during progression of heart dis-
ease. in addition, it could also be targeted for the treatment 
of metabolic syndrome.63,67
interestingly, some studies provide evidence that mirNAs 
also play a functional role in the process of aging. impor-
tantly, the mean age of today’s patients is steadily increasing, 
rising the demand for special attention to the particular con-
ditions of older patients. Aging itself represents a risk factor 
in the perioperative setting, especially with regard to cardio-
vascular disease.69 Physiologic changes that come with age 
also include alterations in mirNAs expression and function. 
consequently, recent studies indicate that mirNAs play 
important functional roles in the process of aging.70,71 one 
of these age-associated mirNAs is mir-34a. A study analyz-
ing the mirNA expression levels in human heart samples 
revealed that the level of expression of mir-34a significantly 
correlated with the patient’s age when a cardiac biopsy was 
obtained. subsequent mechanistic studies demonstrated 
that mir-34a contributes to an age-related cardiac function 
deterioration in the murine heart.72 Mir-34a interaction 
with phosphatase nuclear targeting subunit (PNUTs), also 
known as protein phosphatase 1, regulatory subunit 10 (also 
known as PPP1r10) promotes telomere attrition and cell 
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death, thereby worsening the postinfarct cardiac function 
in the aged murine heart (fig. 4). PNUTs is predominantly 
localized to the interphase nucleus of mammalian cells. it 
can interact with the telomere-specific proteins, for example, 
telomere repeat factor 2,73 and is thought to function in 
the DNA damage response in DNA repair.74 In vivo inhibi-
tion of mir-34a prevented PNUTs down-regulation. As a 
result, higher levels of PNUTs prevented telomere shorten-
ing, reduced cardiomyocyte cell death, and improved cardiac 
contractility after myocardial infarction in older mice.72 The 
findings indicate that preventing mir-34a from regulatory 
activity attenuates cardiac injury in elderly. Therefore, it is 
conceivable that when patients undergo interventions associ-
ated with a high risk for cardiac complications, inhibition of 
mir-34a could specifically improve perioperative outcomes 
in elderly patients.
Inflammation and Sepsis
inflammation and sepsis occur frequently and represent 
major contributing factors to morbidity and mortality in 
perioperative medicine and during critical illness. in the 
following paragraph, we will highlight the roles of three 
mirNAs that were found to be important in assuring proper 
immune responses. As first, we will discuss mir-223 as a 
key regulator of innate immune responses. second, we will 
describe findings on mir-146a that has been implicated in 
the function of regulatory T cells (Tregs) and their concomi-
tant role in the resolution of inflammation. Finally, we will 
review studies of mir-27a as a biomarker and functional tar-
get mirNA during sepsis.
Effective responses to infectious or sterile immune 
stressors require tightly controlled and precisely regulated 
inflammatory cascades to be activated. At the same time, 
certain endogenous and exogenous signals have to be down- 
regulated in order to prevent collateral tissue damage or pro-
gression to chronicity. representing a fast reacting group of 
fine-tuning regulators, it is not unexpected that mirNAs 
have been shown to play an important role in control-
ling inflammation and immune responses.14,75,76 They are 
involved in the regulation of innate and adaptive immune 
responses, dynamically regulating proliferation, differentia-
tion, and function of immune cells and thereby controlling 
a wide range of immune responses.75–79 A key mirNA in 
this process is presented by mir-223, which has been shown 
to modulate innate immune responses on two distinct 
levels. on the one hand, it directly controls granulocyte 
cell differentiation and maturation.80 in addition, it also 
regulates granulocyte function, thereby acting as an impor-
tant regulatory break for granulocyte activity.81 Mice with 
mir-223 deletion are prone to inflammation. When chal-
lenged with endotoxin, mir-223 knockout mice display 
exaggerated tissue injury and develop profound pulmonary 
Fig. 4. MicroRNA miR-34a in the aged heart. In the aged heart, miR-34a levels are increased. MiR-34a interaction with its tar-
get phosphatase nuclear targeting subunit (PNUTS), also known as protein phosphatase 1, regulatory subunit 10 (PPR1R10) 
mRNA, prevents PNUTS translation. Lower levels of PNUTS promote telomere attrition and cell death, worsening the postinfarct 
cardiac function in the elderly patient. The inhibition of miR-34a by anti-miR-34a allows PNUTS protein synthesis. Higher levels 
of PNUTS prevent telomere shortening, reduce cardiomyocyte cell death, and improve cardiac contractility after myocardial 
infarction in the aged heart. Taken together, these findings suggest that pharmacologic approaches that would inhibit miR-34a 
(e.g., anti-miR-34a) could improve cardiac function in the elderly patient suffering from myocardial infarction.72 RISC = RNA-
induced silencing complex.
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inflammation. one of the critical targets regulated by mir-
223 is the inflammasome NLr family, pyrin domain con-
taining 3 (NLrP3), a multiprotein complex sensing cellular 
stress and mediating inflammatory responses.82 NLrP3 is an 
important regulator of caspase-1, the enzyme regulating the 
level of active interleukin (iL)-1β protein and was shown to 
play a role in the regulation of inflammation and apoptosis. 
it is involved in the pathogenesis of hereditary cryopyrinopa-
thies, a spectrum of autoinflammatory syndromes and was 
also associated with diseases such as gout, type 2 diabetes, 
and atherosclerosis. Mir-223 suppresses NLrP3 expres-
sion through its 3′UTr leading to reduced NLrP3 inflam-
masome activity and therefore limiting proinflammatory 
processes.
Depending on the regulated target gene, mirNAs can 
act as an amplifier of proinflammatory or antiinflamma-
tory signals, meaning that depending on their target genes 
(proinflammatory or antiinflammatory targets), they have 
the capability to enhance or dampen an inflammatory 
immune response. one of the first mirNAs that was shown 
to be induced during inflammation is mir-146a. indeed, 
it was subsequently demonstrated that mir-146a plays 
a central role in controlling innate and adoptive immune 
responses.83–86 Deletion of mir-146a in vivo revealed a 
hyperresponsive and inflamed phenotype, as well as favored 
autoimmunity in mice. Mir-146a was shown to be one of 
the prevalent mirNAs expressed in Tregs, a subpopulation 
of T cells. Tregs are critical for self-tolerance and autoim-
mune disease and play a critical role in promoting the reso-
lution of inflammation.87 Lack of mir-146a is associated 
with increased levels of its direct target signal transducer and 
activator transcription 1 (stat1). in response to stimulation 
by interferons, stat1 induces genes involved in the activation 
of the immune system. it is known for its central role in the 
modulation of the interferon-mediated immune response. 
This immune response is mediated by Th1 helper cells, a 
subpopulation of T effector cells representing the host 
immunity effectors against intracellular bacteria and proto-
zoa. For Treg-mediated control of these Th1 responses, an 
optimal level of stat1 activation is important. Deregulated 
stat1 levels in Tregs lead to loss of appropriate regulation of 
T effector cells and autoimmunity. These findings confirmed 
the studies that had earlier identified mir-146a as negative 
regulator of immune responses, acting as an autoregulatory 
brake in inflammatory feedback loops.84
Postoperative inflammation after surgery is a common 
and usually limited event. But, when paired with an infection 
might lead to sepsis—one of the leading causes of mortality 
on surgical intensive care units.88 Although some patients are 
capable of mounting an adequate inflammatory response after 
surgery, some patients develop severe systemic reactions caused 
by inadequate immune response. mirNAs have been shown 
to be highly involved in the complex regulation of adequate 
immune responses.75,76,89–91 Very recent findings from a func-
tional study in a murine sepsis model revealed expressional 
changes of diverse mirNAs including the proinflammatory 
mir-27a during sepsis induction.92 Previous studies revealed 
that the antiinflammatory gene peroxisome proliferator–
activated receptor (PPAr) γ is one of the several genes mir-
27a can target and reported that it is negatively regulated by 
mir-27a in adipocyte differentiation.93 The three different 
PPArs, α, β/δ, and γ, are differentially expressed and repre-
sent nuclear receptor proteins that function as transcription 
factors. PPArs play essential roles in the regulation of various 
biological functions. in particular, PPArα and PPArγ have 
been implicated in the regulation of inflammatory responses 
in different cell types. Based on this, the authors examined 
the neutralization of mir-27a in a murine cecal ligation and 
puncture sepsis model.92 in those septic mice, inhibition of 
mir-27a was accompanied by reduced expression levels of pro-
inflammatory cytokines such as tumor necrosis factor-α and 
iL-6 and diminished pulmonary inflammation and revealed 
a benefit in survival of septic mice. This is also in accordance 
with a study that identified iL-10, a major antiinflammatory 
cytokine, as direct mir-27a target in human peripheral blood 
mononuclear cells.94 Based on these findings, mir-27a is a top 
candidate target for mirNA-based sepsis therapeutics.
Infections with Pathogens
Besides, mirNAs controlling the host’s defense mechanisms, 
mirNAs can also directly interact with invading pathogens, 
such as viruses.95–97 in the following paragraph, we will 
highlight the involvement of mirNAs in controlling infec-
tions based on the studies of mice deficient in the mirNA- 
editing enzyme Dicer. second, we will discuss the role of 
liver-specific mir-122 during hepatitis c. indeed, these 
findings have led to one of the first successful clinical trials 
directly targeting an mirNA for disease treatment.
one of the key steps in the maturation process of 
mirNAs involves rNA processing by Dicer. As such, 
impaired mirNA maturation in models of dicer deficiency 
highlights the roles of mirNAs in controlling infections with 
pathogens. initial studies in Dicer-deficient mice revealed 
impaired overall mirNA production. Because homozygous 
mice with targeted deletion of Dicer die during the early 
embryogenesis due to developmental defects, mice carrying 
a hypomorphic Dicer1 allele (Dicer [d/d]) can be used to 
bypass the embryonic lethality. These mice with partial dicer 
deficiency are vital and can be used to examine the func-
tional role of dicer in a wide set of disease models.98 indeed, 
dicer deficiency was associated with an increased suscepti-
bility to viral infections, thereby revealing a pivotal role for 
mirNAs in viral infections.99 Dicer1 (d/d) mice experienced 
an increased susceptibility to vesicular stomatitis virus infec-
tion. At least in part, this phenotype was caused by a lack of 
mir-24 and mir-93, which are known to target viral proteins, 
and are, therefore, critical in attenuating viral replication. in 
summary, these findings indicate that the iFNβ-induced 
antiviral effects on hepatitis c virus (HcV) replication and 
infection are at least in part mirNA mediated.
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A well-studied mirNA involved in the control of virus 
infection is the liver-specific mirNA mir-122. in contrast to 
most other mirNAs, this mirNA is known to preferentially 
bind to the 5′UTr of its target mrNA (or to viral rNA). 
importantly, mir-122 binding to the 5′UTr of its target 
causes increased expression of its target. in other words, bind-
ing of mir-122 to its target promotes expression of its tar-
get gene. indeed, mir-122 was shown to directly bind to the 
HcV rNA, and thereby promoting its replication by vari-
ous mechanisms, including direct binding to the 5′UTr of 
the viral genome,31 as well as by stimulation of viral protein 
translation100 and delayed decay of the HcV rNA in infected 
cells101 (fig. 5). studies revealed that specific inhibition of this 
particular mirNA efficiently suppresses virus replication. This 
finding was first shown in simple cell culture experiments. The 
inhibitory compound, sPc 3649 (miravirsen), is an antisense 
oligonucleotide that is complementary to mir-122. it binds 
with a high affinity and specificity to mir-122. sequestering 
of mir-122 prevents mir-122 from protecting HcV mrNA 
and from stimulating its translation (fig. 5). in subsequent 
studies, the antiviral effect of mir-122 inhibition was also 
successfully translated in nonhuman primates.102 inhibi-
tion of mir-122 in chronically infected chimpanzees lead to 
long-lasting suppression of HcV viremia and derepression 
of mir-122 target mrNAs. Although the treated animals 
showed no side effects during treatment, their liver biopsies 
revealed improved HcV-induced liver pathology. Following 
these studies, subsequent studies took these findings from the 
research laboratory into a clinical setting. indeed, the antivi-
ral effect of mir-122 inhibition was proven and confirmed in 
humans.103 in a randomized study, 36 patients suffering from 
chronic HcV genotype 1 infection received five weekly injec-
tions of sPc 3649 at different doses (3, 5, or 7 mg/kg of body 
weight) or placebo. sPc 3649 was reconstituted to a concen-
tration of 150 mg/ml and was administered subcutaneously 
over a 29-day period. All patients were followed for 18-week 
postrandomization. The sPc 3649 treatment resulted in a 
dose-dependent reduction in HcV rNA levels lasting beyond 
the 29-day period of therapy. in addition, in some patients 
who received higher doses of sPc 3649, HcV rNA was not 
detected in the 14 weeks of follow-up after treatment. Among 
all patients, there were no dose-limiting adverse events and 
also no escape mutations in the mir-122-binding sites of the 
HcV genome were discovered. Today, the specific mirNA-
122 inhibitor sPc 3649 is the first mirNA therapeutic that 
successfully entered a clinical phase ii.103
Biomarker
MicrorNAs are likely to “experience” their first success-
ful integration into routine clinical practice based on their 
Fig. 5. MicroRNA miR-122 in hepatitis C virus (HCV) infection. After infection of a hepatocyte with the HCV, miR-122 promotes 
virus replication via different mechanisms. In contrast to the typical location of the microRNA binding in the 3 prime untranslated 
region (3′ UTR) of the target mRNA, miR-122 binds in the 5 prime untranslated region (5′UTR) of its target gene, the HCV mRNA. 
Opposite to target gene repression via binding to the 3′UTR, miR-122 binding in the 5′ UTR and recruiting RNA-induced silenc-
ing complex (RISC) stimulate viral protein translation and stabilize the viral mRNA thereby promoting the propagation of HCV. 
SPC 3649 (Miravirsen), a locked nucleic acid oligonucleotide that binds to and sequesters miR-122, results in functional miR-
122 inhibition. A study with 36 patients with chronic HCV genotype 1 infection who received five weekly subcutaneous injections 
of SPC 3649 resulted in prolonged dose-dependent reductions in HCV RNA levels. The patients received doses of 3, 5, or 7 mg/
kg of body weight or placebo subcutaneously over a 29-day period and had been followed until 18 weeks after randomization. 
The study revealed no evidence of viral resistance or dose-limiting side effects.103
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applicability as biomarkers of various disease processes. Due 
to their high abundance and stability and the ease in access-
ing them in body fluids, this could be particular relevant to 
the field of perioperative medicine. Expression levels of cir-
culating mirNAs are significantly altered in various diseases 
indicating that they may serve in diagnosis and prognosis 
of disease, in monitoring treatment responses, and in evalu-
ating perioperative risks. changes in extracellular mirNA 
expression can occur due to damaged tissue where cells sim-
ply release their contained intracellular mirNAs. in other 
cases, extracellular mirNAs could be actively transcribed, 
secreted, and transferred to other cells as part of a cellular 
response and in order to interact with other cell types. in the 
cancer field, the potential diagnostic and prognostic value of 
circulating mirNAs is already well established. For example, 
a large prospective mirNA profiling study (phase iii, clini-
calTrials.gov identifier: NcT02247453) used plasma from 
volunteers who are heavy smokers and assessed mirNA 
expression as a first-line screening test for lung cancer detec-
tion (table  1). Although the development of mirNAs in 
the cancer field is very advanced, other fields are catching 
up. Analysis of human plasma from patients with acute 
coronary occlusion revealed highest sensitivity and specific-
ity for mir-208a for the early diagnosis of acute myocardial 
infarction.104 subsequent studies in a rat model of myo-
cardial infarction revealed that mir-208a was undetected 
in plasma samples at 0 h but was significantly increased as 
early as 1 h postcoronary artery occlusion, presumably due to 
release from the injured myocardium. in patients with acute 
myocardial infarction, mir-208a appeared in less than 4 h 
after the onset of chest pain, with levels correlating with later 
peaking troponin and infarct size.
in patients suffering from sepsis, analysis of circulating 
mirNA levels revealed dynamic changes that correlate with 
different stages of disease, prognosis, and outcome.92,105–107 
Analysis of extracellular mirNAs could also help iden-
tifying the early onset of acute kidney injury (AKi). Kid-
ney failure presents a frequent perioperative complication, 
and even minor increases of perioperative creatinine levels 
are associated with prolonged hospital length of stay and 
increased mortality.108 studies revealed that during kid-
ney injury, mir-210 was up-regulated in plasma samples 
derived from AKi patients.109 Moreover, circulating levels of 
mir-210 were shown to correlate with outcome of critically 











Ulcerative colitis, Crohn’s disease, 
healthy non-IBD colitis
Evaluate the diagnostic value of miRNAs 
for inflammatory bowel disease
NCT02020382 (recruiting)
Asthma (budesonide) Asthmatics, healthy nonasthmatic 
controls
Evaluate the role of miRNAs in Th2-
driven inflammation in asthma
NCT01484691 (recruiting)
PAH Patients undergoing right heart 
 catheterization for PAH diagnosis as 
part of their clinical care, controls: 
patients who present with symptoms 
of PAH and whose clinical right heart 
catheterization does not support this 
diagnosis
Analyze the expression and signifi-
cance of miRNA profile and markers 
of inflammation in patients with PAH
NCT00806312 (recruiting)
Postoperative 
delirium in patients 
undergoing hip 
arthroplasty
Hypoactive and hyperactive delirious 
patients, patients not presenting any 
symptoms of hypoactive or hyperac-
tive postoperative delirium
Identification of specific circulating 
miRNAs and microemboli formation 
(diagnosed by TC Doppler) in both 
delirious groups and nondelirious 
group
NCT02323984 (recruiting)
AKI in postcardiac 
surgery
Adult cardiac surgery patients (> 16 yr) 
undergoing coronary artery bypass 
grafting or valve surgery with moder-
ately hypothermic blood cardioplegia 
at increased risk for AKI
Identify the role of microvesicles and 
microvesicle-derived miRNA in 




chial  segmental 
 endotoxin 
 instillation, 4 ng/kg)
Healthy individuals (18–45 yr) with 
no significant medical problem, no 
 medication, nonsmoker
Identification of cell-associated and 
secreted miRNAs with specific types 
of resident and inflammatory cells in 
the lung
NCT02392442 (recruiting)
Cardiac arrest Patients with cerebral performance 
 category score 1–2 vs. 3–5 judged 
half a year after cardiac arrest
Evaluate the plasma levels of miRNAs 
and circular RNAs after cardiac arrest 
and their ability to prognosticate 
neurologic outcome
NCT02297776 (recruiting)




Patients with primary liver cancer or 
those with liver metastasis from other 
cancers
Evaluate the safety of MRX34 
( multicenter phase I study)
NCT01829971 (recruiting)
AKI = acute kidney injury; IBD = inflammatory bowel disease; miRNA = microRNA; PAH = pulmonary arterial hypertension.
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ill patients suffering from AKi. This study suggested that 
mir-210 is an independent and powerful predictor of 28-day 
survival. This indicates that mir-210 could be used as novel 
biomarker of stratifying the prognosis of critically ill patients 
with AKi.109 some mirNAs (e.g., mir-494) also showed 
altered expression in urine samples providing an additional 
source for detecting mirNAs during AKi.110 interestingly, 
it was shown that during AKi, many mirNA alterations in 
serum or urine can be detected even before serum creati-
nine starts increasing.110 consequently, these mirNAs have 
great potential as biomarkers, as they might allow an earlier 
diagnosis leading to an earlier onset of therapy resulting in 
benefit in patient outcome.
currently, a major challenge for the field of mirNA bio-
markers represents the technical difficulty for mirNA mea-
surements using standardized technology. still, more specific 
and sensitive mirNA detection methods are needed that help 
illuminating their role in diverse disease and critical health 
states. Working with reliable and reproducible mirNA mea-
surement technologies will increase the opportunities to 
benefit from mirNAs in perioperative medicine.111
Pharmacologic Functions of miRNAs and 
miRNA Therapeutics
Effects of miRNA on Drug Metabolism
recent studies elucidated an important role of mirNAs in 
mediating and modulating the effects of various common 
drugs. it is not surprising that this field of research has gen-
erated considerable interest for the mirNA field, including 
its application in perioperative medicine.112–115 similar to 
any other target gene, mirNAs can target genes that code 
for enzymes that are important for drug metabolism. Based 
on so-called mirNA pharmacogenomic studies, differing 
mirNA expression levels can affect the ability of drugs to 
be activated, thereby altering a drug’s efficiency or toxic-
ity.116–118 A conceivable scenario would be an mirNA target 
that serves as binding partner or transporter for a specific 
drug. in cases where the desired protein is reduced due to 
mirNA-mediated gene regulation, the drug efficiency will 
be equally reduced, resulting in insufficient therapy. in the 
opposite situation, mirNAs could exaggerate drug effects 
by repressing drug metabolism. Thereby, drug dosages could 
reach toxic levels.
A very prominent drug metabolizer is the cytochrome 
cYP3A4 protein. it is relevant for the turnover of more than 
50% of commonly used drugs.119 Human drug responses 
are highly dependent on the individual expression level of 
cYP3A4; therefore, the regulation of this master metabo-
lizer is equally regulating the resulting drug-induced effects. 
so far, there are various reports about mirNAs regulating 
cYP3A4, but only a few mirNAs have been identified that 
are likely to have a profound regulatory impact on drug effi-
ciency.120 studies in human liver biopsies revealed a signifi-
cant linear correlation of four mirNAs, mir-577, mir-1, 
mir-532-3p, and hsa-mir-627 with reciprocal translational 
efficiency of cYP34A. subsequent functional analysis con-
firmed direct targeting of cYP3A4 by mir-577, mir-1, 
mir-532-3p, and mir-627 and repression of protein syn-
thesis of cYP3A4. Therefore, these mirNAs serve as top 
candidates contributing to the interindividual variability 
in cYP3A4 levels in human population. Possibly affecting 
a large group of patients, ongoing studies investigate the 
possibility that the pharmacologic efficiency of the antico-
agulant warfarin could be affected by mirNAs. Due to its 
narrow therapeutic window, knowledge about additional 
regulatory levels of warfarin metabolism and action could 
help avoid adverse drug events. cYP1A1, one of the enzymes 
responsible for warfarin metabolism, contains a binding site 
for mir-125b and was experimentally shown to be regulated 
by mir-125b.121 The vitamin K epoxide reductase complex 
subunit 1 (VKorc1) gene, the molecular target for warfa-
rin, was also found to carry two binding sites for mirNAs, 
mir-133 and mir-137.122 studies in human liver samples 
from healthy subjects revealed a significant and inverse cor-
relation between mir-133a and VKorc1 levels, indicating 
that mir-133a might be involved in regulation of VKorc1 
expression. results from different subsequent experimental 
approaches delivered evidence that mir-133a can regulate 
VKorc1 expression.122 These findings illustrate a high like-
lihood that these mirNAs effecting warfarin efficiency are 
clinically relevant and make it highly plausible that antico-
agulatory therapy in future could be optimized and made 
safer by monitoring or modulating specific mirNA levels.
Role of MiRNAs in Mediating Anesthetic Toxicity
A research direction that is currently under intense investiga-
tion and excitement for the field of perioperative medicine is 
the area of anesthetic neurotoxicity, relating to the potential 
neurotoxic effects of commonly used anesthetics, in particular 
in newborn and infants.123,124 These studies associate exposure 
to common anesthetics with neurodegenerative and abnormal 
processes in the developing brain, which may affect learning 
and behavior in the course of later life.125–128 Although ini-
tial studies were performed in immature rodent pups, recent 
studies also include evidence from nonhuman primates.129,130 
interestingly, mirNAs have been investigated in this context. 
To date, a number of in vitro studies confirm mirNA expres-
sion changes after exposure to volatile anesthetics.131–133 other 
studies demonstrated effects of propofol on human stem cells, 
leading to alterations in mirNA expression levels.15,134 in 
addition, some recent studies also indicate functional relevance 
for certain mirNAs in the pathogenesis or protection from 
neurotoxicity, respectively. Moreover, some mirNAs have 
already been identified to present potential targets that could 
be modulated to enhance the mirNA-mediated neuroprotec-
tive effects.15,16,135 For example, studies examining the human 
embryonic stem cell–derived neurons in vitro identified a rel-
evant role for mir-21 in anesthetic-induced  neurotoxicity.15 
The findings of this study showed that propofol-induced 
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cell death in human embryonic stem cell–derived neurons 
involved down-regulation of mir-21 and subsequently 
resulted in an increased expression of its target gene sprouty 
2 (sPrY2), a regulator of multiple receptor tyrosine kinases. 
sPrY2 acts as negative feedback regulator of multiple receptor 
tyrosine kinases causing attenuation of growth factor–medi-
ated pathways, such as cell migration and cellular differen-
tiation. Experimental overexpression of mir-21 significantly 
attenuated cell death of human embryonic stem cell–derived 
neurons induced by propofol. consequently, reversing the 
propofol-induced down-regulation of mir-21 could play a 
pivotal role in protecting from anesthetic-induced neurotox-
icity. At this point, confirmatory functional studies in vivo 
are the next step to take. For example, studies in mice with 
genetic deletion of mir-21 could help to further identify a 
functional role of mir-21 in anesthetic-induced cell death. 
Based on these findings, the prediction would be that mir-21 
knockout mice receiving propofol are protected from neuro-
nal cell death via targeting genes attenuating the mediation 
of anesthesia-induced neurotoxic effects. Moreover, studies 
examining mirNA expression levels in patients undergoing 
propofol anesthesia would be important to help transitioning 
this area of research from bench to bedside.
similar to the study mentioned in the previous paragraph, 
investigations in rats at the age of 1 month who received 
ketamine anesthesia revealed ketamine-induced apoptosis of 
hippocampal neurons, memory deficiency, and significant 
down-regulation of mir-137.16 Pretreatment with mir-137 
via lentiviral-mediated mir-137 overexpression protected 
from hippocampal neurodegeneration and long-term mem-
ory dysfunction. Again, more functional studies in genetic 
models are needed to confirm these results. subsequent 
steps will also need to include the identification of relevant 
mirNA target genes that could be modulated. surprisingly, 
at present, there is only very limited availability of data from 
human studies focusing on the role mirNAs during anes-
thesia. For example, further analysis of mirNAs comparing 
expression patterns pre- and postanesthesia in patient popu-
lations exposed to different types of anesthetic agents will 
be of relevance to help study human mirNA responses to 
anesthetics in vivo.
Pharmacologic Approaches Targeting miRNAs
miRNA Inhibition. MicrorNAs represent a novel group of 
gene regulators that can be targeted for therapeutic treat-
ment. From a pharmacologic perspective, targeting mir-
NAs, in particular suppressing them, can be achieved 
relatively easily and reliably. Based on a large number of 
successful experimental loss-of-function studies, current 
effort is focused on developing reliable methods to inhibit 
specific mirNAs in vivo to repress their unwanted function 
in disease. The inhibition of mirNA functions is usually 
obtained by using chemically modified oligonucleotides, 
named anti-mirs, or so-called “mirNA sponges.” mirNA 
sponges represent rNA produced from transgenes within 
the cells, with complementary binding sites to the mirNA 
of interest. MirNA sponges—blocking mirNAs by acting 
as competitive inhibitor—serve as excellent experimental 
devices. However, from a therapeutic perspective, anti-
mirs represent the more promising approach (fig.  6). in 
fact, several modifications have been tested over the last 
Fig. 6. Pharmacologic approaches to target microRNAs (miRNAs). miRNAs can be targeted for treatment. (A) Chemically 
modified RNA molecules can function as miRNA inhibitors (anti-miRs). They bind to specific endogenous miRNAs and inhibit 
their function. This will rescue a specific miRNA from miRNA-mediated regulation. The most successful chemical modification 
increasing the hybridization properties of the RNA molecule are locked nucleic acids (LNAs). An anti-miR that recently success-
fully entered a clinical phase II study is SPC 3649 that binds to and blocks the function of miR-122, an miRNA that is required 
for the hepatitis C virus replication.103 (B) miRNA mimics are double-stranded miRNAs that intend to mimic the endogenous 
miRNA. They comprise the same nucleotide sequence as the desired endogenous miRNA and are designed to target the same 
mRNAs by binding in the 3 prime untranslated region (3′UTR) and recruiting RNA-induced silencing complex (RISC). A miR-34 
mimic, MRX34, currently entered a phase I clinical trial (ClinicalTrials.gov identifier: NCT01829971) to be tested in patients 
with primary liver cancer or patients with liver metastasis from other cancers. In this study intended to investigate safety, 
pharmacokinetics, and pharmacodynamics of MRX34, the drug will be administered intravenously (IV). 2′-OMe = 2′-O-methyl; 
2′-OME = 2′-O-methyoxyethyl; s.c. = subcutaneously.
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decade with the goal to optimize binding affinity, stabil-
ity, and pharmacokinetics of designed oligonucleotides. 
Also, the desired therapeutic modifications should reduce 
any off-target effects and unwanted immune responses and 
avoid interference with the endogenous mirNA machin-
ery. Examples for these modifications at the 2′ position of 
the sugar ring are 2′-O-methyl, 2′-O-methyoxyethyl, and 
LNA modifications (fig. 6). The most successful modifica-
tion getting closest to fulfilling all the criteria mentioned in 
this paragraph, and providing strongest nuclease resistance 
as well as exhibiting highest rNA affinity, are sugar-mod-
ified LNAs. Here, the ribose is “locked” by a bridge con-
necting the 2′ oxygen and 4′ carbon in the rNA molecule. 
in addition, antisense oligonucleotides containing LNAs 
have been shown to be nontoxic and produce high in vivo 
efficiency.136 Targeting disease-associated mirNAs implies 
a very potent approach because mirNAs usually have sev-
eral targets within a pathway and could therefore modulate 
the underlying disease mechanisms efficiently via targeting 
several key proteins.
The mirNA-122 inhibitor named sPc3649 (mira-
virsen; santaris Pharma, Denmark) also represents an LNA. 
sPc3649 robustly inhibited mir-122 function in liver cells 
ex vivo137 and was further shown to inherit a high efficiency 
in antagonizing mir-122 in mice in vivo138 and the same 
could later be confirmed in primates.137 in addition, subse-
quent favorable results from the preclinical toxicology stud-
ies in monkeys paved the way for sPc3649 into clinics.139 
Today, sPc3649 represents the very first mirNA-targeted 
drug that progressed to clinical phase ii of the first human 
trial modulating an mirNA.103
At this point, it is important for the clinicians to be 
aware of possible interactions of mirNA therapy with its 
targets. For example, the same mirNA that is worth block-
ing in one disease condition could be harmful if suppressed 
in another situation. in cancer, a prominent mirNA that 
was shown to act “good” or “bad” depending on the tumor 
entity is mir-125b.140 similar scenarios where positive and 
negative effects of one specific mirNA are conflicting can 
be easily imagined. For example, clinical trials have not 
revealed any adverse side effects for sPc 3649. However, 
in situations where patients are suffering from additional 
disease and/or undergoing a stress situation (e.g., major 
surgery), unwanted effects might occur. The mirNA ther-
apy that protects in a certain primary disease, here anti-
mir-122 in HcV, could harm the patient by preventing 
a desired mirNA-mediated effect (e.g., organ protection 
during liver surgery). For example, a study in genetic mod-
els demonstrates that deletion of mir-122 in mice resulted 
in liver pathologies including hepatosteatosis, hepatitis, 
and the development of tumors resembling Hcc.141 These 
findings indicating antiinflammatory and antitumorigenic 
functions of mir-122 should be taken under critical con-
sideration in patients who are subjected to HcV therapy 
containing anti-mir-122 substances.142
miRNA Overexpression. Although progress in therapeutic 
inhibition of mirNAs has already reached clinical phase 
ii (table 1), the approach of restoring mirNA functions is 
more difficult and challenging. The goal of mirNA overex-
pression is to restore the lost or reduced mirNA expression 
but at the same time to avoid side effects from nonphysi-
ologic high mirNA levels. Moreover, the chemical structure 
of mirNA mimetics has to be as close to its physiologic 
appearance as possible to allow for normal loading into the 
risc complex and resulting in the desired effects mediated 
by the mirNA of interest. The big challenge here is to meet 
desired opposing requirements: restore a close-to-physi-
ologic-structured mirNA for optimal function and avoid 
nonphysiologic mirNA levels to prevent adverse side effects, 
but also modify the agent to ensure efficient and controlled 
cellular uptake. To reintroduce mirNAs, either synthetic 
mirNAs, so-called mimics, or viral vector–based mirNA, 
overexpression is used (fig.  6). mirNA mimics represent 
double-stranded mirNAs with chemical modifications 
improving their stability and increasing probability of their 
cellular uptake. The strand that is identical to the mirNA 
of interest is ensuring the risc-loading process—similar as 
with the native mirNA. Therefore, its modification is mini-
mized. in contrast, the partner strand is modified to improve 
the mimic’s properties. To prevent rNA degradation and to 
enhance stability and cellular uptake, the mimics frequently 
have to be packaged into lipid emulsions.143 Because in 
cancer, it was found that mirNAs are often lost or down-
regulated,3 there is a high interest for developing mirNA 
replacement therapies. Although various cancer tissues have 
been screened and revealed specific aberrant mirNA expres-
sion patterns,3 still only few mirNAs have been analyzed 
functionally in depth. one of those is mir-34a. Mir-34a 
plays a key role as master regulator of tumor suppression. 
strikingly, this antitumor activity of mir-34 revealed pro-
found effects in a mouse model of hepatocellular carcinoma 
after its systemic delivery.144,145 Based on these and other 
studies, mir-34a recently became the pioneer mirNA in 
mirNA-based replacement therapies to enter the clinic. 
in 2013, a mir-34a analog (MRX34) has become the first 
mirNA mimic to enter a phase i clinical trial (clinicalTri-
als.gov identifier: NcT01829971). MRX34 is currently 
tested in patients with unresectable primary liver cancer 
or advanced or metastatic cancer with liver involvement or 
hematologic malignancies. According to the study design, 
MRX34 is administered iV in two different regimes, twice a 
week for 3 weeks with 1 week off or daily for 1 week with 2 
weeks off. The present trial is focused on safety, pharmaco-
kinetics, and pharmacodynamics. Nevertheless, this clinical 
trial represents an important landmark in the development 
of mirNA-based therapeutics.
oncologic surgery is represents a rapidly growing field of 
surgical interventions—mainly related to the fact that patients 
at advanced ages are more likely to experience neoplastic 
diseases. cancer patients usually receive chemotherapies or 
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radiotherapies before or after a surgical intervention. There-
fore, it is feasible that in the imminent future, a patient 
who is undergoing tumor resection will be also receiving an 
mirNA-targeting medication. Therefore, physicians acting 
in the perioperative field will benefit from knowledge about 
the mechanisms and potential side effects of those new thera-
peutic approaches. They may benefit from knowledge of the 
target of the mirNA therapeutics and also their pharma-
codynamics and pharmacokinetics. For example, although 
mir-34a inhibition could be a promising approach in aged 
patients suffering from heart failure or undergoing cardiac sur-
gery,72 the well-known tumor suppressor function of mir-34a 
could be affected in an unwanted direction. Mir-34a mim-
ics have already been shown to qualify for a novel therapeutic 
approach in vivo and in vitro.146 As such, patients who have 
suffered from multiple myeloma, now receiving anti-mir-34a 
for cardioprotection, may simultaneously be at higher risk for 
developing tumor relapse.
The biggest challenge in mirNA-based therapeutics, 
regardless if they are designed to restore or repress mirNA 
functions, is finding a safe and efficient strategy of deliv-
ery. This delivery method needs to assure that the mirNA 
therapeutic reaches its specific target cell and that its local 
concentration is sufficient to induce the desired effect in the 
target cells. currently, the most promising method to deliver 
synthetic double strands is to use agents that form com-
plexes with overexpressing mimics (e.g., liposome nanopar-
ticles).143,147 This method is also used in the first mirNA 
restoring therapy that recently entered clinical phase i.
An additional important aspect of mirNA therapy, includ-
ing anti-mirNA or mirNA mimetic, is drug monitoring. 
Although the plasma levels of mirNA-targeting therapeutics 
are cleared within a short time due to cellular uptake, their 
high metabolic stability provides long half-lives reaching 
weeks to months. consequently, although their blood levels 
are undetectable, their therapeutic effects of mirNA targeting 
may still last.148 Therefore, predictions about pharmacologic 
effects and their duration can only be controlled by analyz-
ing target tissue concentrations. in addition, the “delayed 
nature” of the pharmacologic effects of the mirNA-targeting 
substances is complicating their monitoring. Although the 
particular mirNA is immediately antagonized or acting as 
analog, the downstream effects of derepression or repression 
of families of genes need time, as they predominantly depend 
on the half-life of a specific protein, and half-life of proteins 
are highly variable. in addition, important consideration for 
mirNA therapies is the route of treatment. At present, there 
are no successful oral applications for anti-mirs or mirNA 
mimics available, so that the two application routes currently 
used are iV or subcutaneous injections.
Challenges and Conclusions
The speed the mirNA field developed from bench to bed-
side is remarkable. The entrance into clinical trials of both, 
mirNA-replacement and mirNA-suppression, therapies 
are the most recent achievements in this rapidly evolving 
course. initially, mirNA-based therapies were mainly seen 
in the cancer field. Here, most recent achievements are 
highlighted in successful antitumor treatment in models 
of murine non–small-cell lung cancer and hepatocellular 
cancer.143,145,149 Further preclinical studies with systemic 
delivery of the tumor suppressor mir-34a in various cancer 
models revealed significant tumor growth suppression and 
survival advantage.150,151 These results justified mir-34 to be 
the first mirNA mimic to reach the clinic, currently in a 
multicenter phase 1 clinical trial (table 1; clinicalTrials.gov 
identifier: NcT01829971). Entering the term “mirNA” in 
the search query at clinicalTrials.gov reveals a total of 257 
hits. An extraction of some studies relevant for the peri-
operative medicine displayed in the table 1 highlights that 
mirNA-based therapies are about to reach various fields 
of human disease (table 1). Therefore, it is very likely that 
anesthesiologists will soon be involved in the care of patients 
receiving mirNA-based therapy and should be aware of the 
broad involvement of these small molecules and their impact 
on the posttranslational regulation of gene expression in 
diverse physiologic and pathologic conditions.
Although there are numerous bioinformatic studies 
reporting the changes in mirNA expression levels and cor-
relating those with specific disease components, there are 
many examples where we still lack functional insight toward 
understanding the full impact of mirNA activities in the 
perioperative field. Although there are studies delineating 
mirNA expression in different disease states, we still need 
additional studies to address the functional consequences of 
these differentially expressed mirNAs. What specific down-
stream effects are mediated by aberrantly expressed mirNAs 
and what are the consequences with regard to neurologic and 
immunologic outcome and hemostasis? critical factors for 
a successful mirNA study should include characterization 
of mirNA expression levels, followed by functional inves-
tigations with gain-of-function and loss-of-function stud-
ies. identifying and further verifying a relevant target is the 
biggest challenge of any mirNA study, and consequently 
among the numerous mirNA studies, this key feature is 
only present in the minority of published reports. But the 
more we know about the downstream effects that are caused 
by aberrant expression of specific mirNAs, the more precise 
we can modulate them, monitor therapy, and consequently 
benefit from the potential mirNA-based therapies bear. it 
is conceivable that patients who are at risk for developing a 
specific disease (e.g., AKi) could be treated with an mirNA 
mimic or inhibitor that would dampen the risk for develop-
ing this specific type of organ injury after elective surgery. 
indeed, the fact that many surgical patients are examined 
weeks before an elective surgical intervention would allow 
for preoperative treatment with such medications. similarly, 
we anticipate that additional mechanistic research on the role 
of mirNAs in mediating toxic side effects could ultimately 
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lead to altered anesthetic approaches in patients with specific 
mirNA expression patterns. Taken together, we believe that 
the described emerging roles of mirNAs have many impli-
cations for perioperative medicine and will soon become an 
integral part of the daily practice of anesthesiology, critical 
care, and emergency medicine.
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